FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results
| Autor: | Vânia Nosé, Paula Abreu-e-Lima, Harvey J. Mamon, Marcelo Mamede, M. R. Oliva, Victor H. Gerbaudo |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Adenocarcinoma Disease-Free Survival Fluorodeoxyglucose F18 Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Progression-free survival Neoadjuvant therapy Neoplasm Staging Retrospective Studies PET-CT medicine.diagnostic_test business.industry Esophageal cancer Middle Aged medicine.disease Combined Modality Therapy Neoadjuvant Therapy Esophagectomy Radiography Treatment Outcome Oncology Positron emission tomography Positron-Emission Tomography Carcinoma Squamous Cell Histopathology Female Radiology Radiopharmaceuticals business Tomography Emission-Computed |
| Zdroj: | American journal of clinical oncology. 30(4) |
| ISSN: | 1537-453X |
| Popis: | To evaluate the diagnostic and prognostic abilities of PET tumor segmentation-derived indices of metabolic activity for the assessment of response to neoadjuvant chemoradiotherapy and progression-free survival in patients with esophageal cancer.Twenty-five patients with histologically confirmed esophageal cancer were retrospectively evaluated. The patients underwent PET-CT imaging before and after completion of neoadjuvant therapy. Images were evaluated visually and quantitatively with a three-dimensional threshold-based region-growing program, which calculates SUVm, SUVa of the entire tumor, metabolic tumor length (Lm) and volume (Vm) before and after therapy (SUVm1, SUVm2, SUVa1, SUVa2, Lm1, Lm2, Vm1, and Vm2, respectively). Percentage changes in these metabolic variables before and after therapy were also calculated (%SUVm, %SUVa, %Lm, %Vm, respectively).SUVm1 (P = 0.018), SUVa1 (P = 0.019), Lm1 (P = 0.016), and Vm1 (P = 0.016) correlated with T-status. Advanced stage tumors (T3 + T4) had significantly higher glucose metabolism, metabolic length, and volume. Moreover, Lm147.4 mm and Vm129 cm3 were the best predictors of the level of tumor invasiveness. SUVm112.7 and SUVa15.9 could differentiate patients with positive lymph nodes from those without at presentation. %SUVa32.3% and the SUVa15.5 proved to be reliable predictors of pathologic response. SUVa23.55 and SUVm24.35 were the best predictors of disease progression during follow-up, with the latter having the best prognostic value.This study showed that FDG-PET tumor segmentation-derived indices of metabolic activity play a definite role in the evaluation of response to neoadjuvant chemoradiotherapy and progression-free survival in patients with esophageal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|